Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA's Generics Unit
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy and Actavis are two potential bidders vying for Merck KGaA's generics drug unit, an acquisition that would solidify either company as the third largest generics drug maker in the world